Preemptive rituximab prevents long-term relapses in immune-mediated thrombotic thrombocytopenic purpura.

Preemptive rituximab infusions prevent relapses in immune thrombotic thrombocytopenic purpura (iTTP) by maintaining normal ADAMTS13 activity. However, the long-term outcome of these patients and the potential adverse events of this strategy need to be determined. We report the long-term outcome of 92 patients with iTTP in clinical remission who received preemptive rituximab after identification of severe ADAMTS13 deficiency (activity <10%) during the follow-up. Thirty-seven patients had >1 iTTP episode, and the median cumulative relapse incidence before preemptive rituximab was 0.33 episode per year (interquartile range [IQR], 0.23-0.66). After preemptive rituximab, the median cumulative relapse incidence in the whole population decreased to 0 episodes per year (IQR, 0-1.32; P < .001). After preemptive rituximab, ADAMTS13 activity recovery was sustained in 34 patients (37%) during a follow-up of 31.5 months (IQR, 18-65), and severe ADAMTS13 deficiency recurred in 45 patients (49%) after the initial improvement. ADAMTS13 activity usually improved with additional courses of preemptive rituximab. In 13 patients (14%), ADAMTS13 activity remained undetectable after the first rituximab course, but retreatment was efficient in 6 of 10 cases. In total, 14 patients (15%) clinically relapsed, and 19 patients (20.7%) experienced benign adverse effects. Preemptive rituximab treatment was associated with a change in ADAMTS13 conformation in respondent patients. Finally, in the group of 23 historical patients with iTTP and persistently undetectable ADAMTS13 activity, 74% clinically relapsed after a 7-year follow-up (IQR, 5-11). In conclusion, persistently undetectable ADAMTS13 activity in iTTP during remission is associated with a higher relapse rate. Preemptive rituximab reduces clinical relapses by maintaining a detectable ADAMTS13 activity with an advantageous risk-benefit balance.

[1]  J. Voorberg,et al.  Dissecting the pathophysiology of immune thrombotic thrombocytopenic purpura: interplay between genes and environmental triggers , 2018, Haematologica.

[2]  J. Voorberg,et al.  An open conformation of ADAMTS‐13 is a hallmark of acute acquired thrombotic thrombocytopenic purpura , 2018, Journal of thrombosis and haemostasis : JTH.

[3]  D. Saadoun,et al.  De Novo Human Herpesvirus 8 Tumors Induced by Rituximab in Autoimmune or Inflammatory Systemic Diseases. , 2017, Arthritis & rheumatology.

[4]  A. Davies,et al.  Subcutaneous Rituximab for the Treatment of B-Cell Hematologic Malignancies: A Review of the Scientific Rationale and Clinical Development , 2017, Advances in Therapy.

[5]  J. Sadler,et al.  Pathophysiology of thrombotic thrombocytopenic purpura. , 2017, Blood.

[6]  M. Scully,et al.  Rituximab prophylaxis to prevent thrombotic thrombocytopenic purpura relapse: outcome and evaluation of dosing regimens. , 2017, Blood advances.

[7]  P. Coppo,et al.  Thrombotic thrombocytopenic purpura. , 2017, Blood.

[8]  G. Salles,et al.  Rituximab maintenance improves overall survival of patients with follicular lymphoma-Individual patient data meta-analysis. , 2017, European journal of cancer.

[9]  Karen Vanhoorelbeke,et al.  Thrombotic thrombocytopenic purpura , 2017, Nature Reviews Disease Primers.

[10]  E. Biganzoli,et al.  ADAMTS13-specific circulating immune complexes as potential predictors of relapse in patients with acquired thrombotic thrombocytopenic purpura. , 2017, European journal of internal medicine.

[11]  K. McCrae,et al.  Post-traumatic stress disorder and depression in survivors of thrombotic thrombocytopenic purpura. , 2017, Thrombosis research.

[12]  P. Coppo,et al.  Consensus on the standardization of terminology in thrombotic thrombocytopenic purpura and related thrombotic microangiopathies , 2017, Journal of thrombosis and haemostasis : JTH.

[13]  S. Vesely,et al.  Rituximab reduces risk for relapse in patients with thrombotic thrombocytopenic purpura. , 2016, Blood.

[14]  A. Cuker.  Adjuvant rituximab to prevent TTP relapse. , 2016, Blood.

[15]  G. Salles,et al.  Rituximab and risk of second primary malignancies in patients with non-Hodgkin lymphoma: a systematic review and meta-analysis. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[16]  D. Chauveau,et al.  Risk Factors for Autoimmune Diseases Development After Thrombotic Thrombocytopenic Purpura , 2015, Medicine.

[17]  C. Abrams,et al.  How I treat refractory thrombotic thrombocytopenic purpura. , 2015, Blood.

[18]  S. Cataland,et al.  Headache prevalence following recovery from TTP and aHUS , 2015, Annals of Hematology.

[19]  S. Vesely,et al.  The role of rituximab in the management of patients with acquired thrombotic thrombocytopenic purpura. , 2015, Blood.

[20]  L. Galicier,et al.  Preemptive rituximab infusions after remission efficiently prevent relapses in acquired thrombotic thrombocytopenic purpura. , 2014, Blood.

[21]  S. Vesely,et al.  Multiple major morbidities and increased mortality during long-term follow-up after recovery from thrombotic thrombocytopenic purpura. , 2013, Blood.

[22]  G. Choukroun,et al.  Efficacy and safety of first-line rituximab in severe, acquired thrombotic thrombocytopenic purpura with a suboptimal response to plasma exchange. Experience of the French Thrombotic Microangiopathies Reference Center , 2012, Critical care medicine.

[23]  Shili Lin,et al.  ADAMTS13 activity and antigen during therapy and follow-up of patients with idiopathic thrombotic thrombocytopenic purpura: correlation with clinical outcome , 2011, Haematologica.

[24]  J. Cavenagh,et al.  A phase 2 study of the safety and efficacy of rituximab with plasma exchange in acute acquired thrombotic thrombocytopenic purpura. , 2011, Blood.

[25]  P. Maruff,et al.  Evidence of persistent neurologic injury following thrombotic thrombocytopenic purpura , 2011, American journal of hematology.

[26]  David Green,et al.  Progressive multifocal leukoencephalopathy after rituximab therapy in HIV-negative patients: a report of 57 cases from the Research on Adverse Drug Events and Reports project. , 2009, Blood.

[27]  S. Vesely,et al.  Complications of plasma exchange in patients treated for thrombotic thrombocytopenic purpura. IV. An additional study of 43 consecutive patients, 2005 to 2008 , 2009, Transfusion.

[28]  F. Fabris,et al.  ADAMTS13 and anti-ADAMTS13 antibodies as markers for recurrence of acquired thrombotic thrombocytopenic purpura during remission , 2008, Haematologica.

[29]  É. Oksenhendler,et al.  Prognostic value of anti-ADAMTS 13 antibody features (Ig isotype, titer, and inhibitory effect) in a cohort of 35 adult French patients undergoing a first episode of thrombotic microangiopathy with undetectable ADAMTS 13 activity. , 2007, Blood.

[30]  J. Cavenagh,et al.  Remission in acute refractory and relapsing thrombotic thrombocytopenic purpura following rituximab is associated with a reduction in IgG antibodies to ADAMTS‐13 , 2007, British journal of haematology.